A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

This study is testing a new treatment called T3011 — a modified virus combined with an immune-boosting molecule — injected directly into the bladder to treat early-stage bladder cancer that has not responded to standard BCG treatment (a common bladder cancer therapy). **You may be eligible if...** - You are 18 years or older - You have non-muscle-invasive bladder cancer (cancer that has not spread into the bladder wall muscle) - Your cancer has not responded to BCG treatment, or you have had chemotherapy but the cancer returned - You are physically well enough to participate (ECOG score 0–2) - Your blood counts, kidney, and liver function meet the required levels **You may NOT be eligible if...** - Your bladder cancer has spread into the muscle wall or to other parts of the body - You have had another cancer (other than this bladder cancer) - You have serious heart problems or poorly controlled blood pressure - You are HIV-positive, have active hepatitis B or C, or other active infections - You have a suppressed immune system or take immunosuppressant drugs - You are pregnant or breastfeeding - You have previously been treated with an oncolytic virus therapy Talk to your doctor to see if this trial is right for you.